PT2737081T - Método para prever a resposta a quimioterapia num doente que sofre de ou em risco de desenvolver cancro de mama recorrente - Google Patents
Método para prever a resposta a quimioterapia num doente que sofre de ou em risco de desenvolver cancro de mama recorrenteInfo
- Publication number
- PT2737081T PT2737081T PT127409746T PT12740974T PT2737081T PT 2737081 T PT2737081 T PT 2737081T PT 127409746 T PT127409746 T PT 127409746T PT 12740974 T PT12740974 T PT 12740974T PT 2737081 T PT2737081 T PT 2737081T
- Authority
- PT
- Portugal
- Prior art keywords
- delegated
- chemotherapy
- patient
- risk
- preventing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11175852 | 2011-07-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2737081T true PT2737081T (pt) | 2016-12-23 |
Family
ID=46598521
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT127409746T PT2737081T (pt) | 2011-07-28 | 2012-07-30 | Método para prever a resposta a quimioterapia num doente que sofre de ou em risco de desenvolver cancro de mama recorrente |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US20140228241A1 (pt) |
| EP (2) | EP2737081B1 (pt) |
| ES (2) | ES2608322T3 (pt) |
| HU (1) | HUE032391T2 (pt) |
| PL (1) | PL2737081T3 (pt) |
| PT (1) | PT2737081T (pt) |
| WO (1) | WO2013014296A1 (pt) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE030164T2 (en) | 2010-03-31 | 2017-05-29 | Sividon Diagnostics Gmbh | A method of predicting breast cancer recurrence during endocrine treatment |
| WO2014118333A1 (en) | 2013-02-01 | 2014-08-07 | Sividon Diagnostics Gmbh | Method for predicting the benefit from inclusion of taxane in a chemotherapy regimen in patients with breast cancer |
| JP6164689B2 (ja) * | 2013-08-30 | 2017-07-19 | 国立大学法人大阪大学 | 乳癌術前化学療法に対する感受性の診断補助方法および判定装置 |
| PL228355B1 (pl) * | 2013-10-15 | 2018-03-30 | Wroclawskie Centrum Badan Eit Spolka Z Ograniczona Odpowiedzialnoscia | Sposób wykrywania obnizonej podatnosci na przeciwnowotworowa chemioterapie adjuwantowa cytostatykiem z grupy oksazofosforyn i antybiotykiem z grupy antracyklin u pacjentów z inwazyjnym przewodowym rakiem gruczołu piersiowego (IDC) |
| US20160348183A1 (en) * | 2014-02-12 | 2016-12-01 | Myriad Genetics, Inc. | Method for predicting the response and survival from chemotherapy in patients with breast cancer |
| CA2990281A1 (en) * | 2015-06-22 | 2016-12-29 | Sunnybrook Research Institute | Systems and methods for prediction of tumor response to chemotherapy using pre-treatment quantitative ultrasound parameters |
| US11497476B2 (en) * | 2015-06-22 | 2022-11-15 | Sunnybrook Research Institute | Systems and methods for prediction of tumor treatment response to using texture derivatives computed from quantitative ultrasound parameters |
| CA3075265A1 (en) | 2017-09-08 | 2019-03-14 | Myriad Genetics, Inc. | Method of using biomarkers and clinical variables for predicting chemotherapy benefit |
| CN113383091B (zh) * | 2018-09-27 | 2025-03-04 | 百欧恩泰诊断有限责任公司 | 乳腺癌的预测和预后方法 |
| EP3887548A1 (en) | 2018-11-30 | 2021-10-06 | GBG Forschungs GmbH | Method for predicting the response to cancer immunotherapy in cancer patients |
| CN113061655B (zh) * | 2021-03-25 | 2022-04-19 | 中国科学院合肥物质科学研究院 | 一组用于预测乳腺癌新辅助化疗敏感性的基因标签及应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008539737A (ja) | 2005-05-13 | 2008-11-20 | ユニヴェルシテ リブル ドゥ ブリュッセル | 遺伝子に基づくアルゴリズム的ガン予後 |
| EP2041307A2 (en) | 2006-07-13 | 2009-04-01 | Siemens Healthcare Diagnostics GmbH | Prediction of breast cancer response to taxane-based chemotherapy |
| WO2009114836A1 (en) | 2008-03-14 | 2009-09-17 | Genomic Health, Inc. | Gene expression markers for prediction of patient response to chemotherapy |
| PT2297359E (pt) | 2008-05-30 | 2014-03-19 | Univ North Carolina | Perfis de expressão de genes para prognosticar resultados relativos ao cancro da mama |
| WO2010076322A1 (en) | 2008-12-30 | 2010-07-08 | Siemens Healthcare Diagnostics Inc. | Prediction of response to taxane/anthracycline-containing chemotherapy in breast cancer |
| HUE030164T2 (en) | 2010-03-31 | 2017-05-29 | Sividon Diagnostics Gmbh | A method of predicting breast cancer recurrence during endocrine treatment |
-
2012
- 2012-07-30 ES ES12740974.6T patent/ES2608322T3/es active Active
- 2012-07-30 HU HUE12740974A patent/HUE032391T2/en unknown
- 2012-07-30 PT PT127409746T patent/PT2737081T/pt unknown
- 2012-07-30 ES ES16184484T patent/ES2714582T3/es active Active
- 2012-07-30 WO PCT/EP2012/064865 patent/WO2013014296A1/en not_active Ceased
- 2012-07-30 US US14/235,168 patent/US20140228241A1/en not_active Abandoned
- 2012-07-30 EP EP12740974.6A patent/EP2737081B1/en active Active
- 2012-07-30 EP EP16184484.0A patent/EP3150720B1/en active Active
- 2012-07-30 PL PL12740974T patent/PL2737081T3/pl unknown
-
2016
- 2016-09-23 US US15/275,150 patent/US20170081728A1/en not_active Abandoned
-
2019
- 2019-01-24 US US16/256,483 patent/US20190144949A1/en not_active Abandoned
-
2022
- 2022-04-06 US US17/714,862 patent/US20220307090A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013014296A1 (en) | 2013-01-31 |
| EP3150720A1 (en) | 2017-04-05 |
| ES2714582T3 (es) | 2019-05-29 |
| EP2737081A1 (en) | 2014-06-04 |
| US20170081728A1 (en) | 2017-03-23 |
| US20220307090A1 (en) | 2022-09-29 |
| EP3150720B1 (en) | 2018-12-12 |
| US20190144949A1 (en) | 2019-05-16 |
| EP2737081B1 (en) | 2016-09-28 |
| PL2737081T3 (pl) | 2017-04-28 |
| US20140228241A1 (en) | 2014-08-14 |
| HUE032391T2 (en) | 2017-09-28 |
| ES2608322T3 (es) | 2017-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2737081T (pt) | Método para prever a resposta a quimioterapia num doente que sofre de ou em risco de desenvolver cancro de mama recorrente | |
| HUE047198T2 (hu) | Fitokannabinoidok emlõrák kezelésére | |
| ZA201605843B (en) | Clinical outcome tracking and analysis | |
| IL226351A (en) | Compounds for preparation of medicaments for treating contrast-induced nephropathy | |
| SI3715345T1 (sl) | Priprava zaviralca lfa-1 | |
| HRP20181628T1 (hr) | Spojevi i postupci za njihovu upotrebu | |
| EP2862082A4 (en) | RESTRICTED TRANSACTION | |
| BR112014009755A2 (pt) | tratamento de câncer com inibidores de quinase tor | |
| IL235307A0 (en) | Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy | |
| EP2834739A4 (en) | TRANSACTION DIAGNOSTICS BLOCK | |
| EP2766301A4 (en) | DRAINING PHOSPHATE PRECIPITATES | |
| HUE045314T2 (hu) | Kombinációs terápia rák kezelésére | |
| BR112013022438A2 (pt) | forma de dosagem de dietilestilbestrol e uso para tratamento de câncer de próstota ou de mama | |
| HUE053156T2 (hu) | Vegyületek agyi áttétek kezelésében történõ alkalmazásra ERBB2+ emlõrákos betegeknél | |
| ZA201401326B (en) | Novel anti-cxcr4 antibody and its use for the detection and diagnosis of cancer | |
| IL238995A0 (en) | A test to detect neutralizing autoantibodies for biological treatment | |
| EP2707710A4 (en) | CANCER DIAGNOSIS | |
| LT2914254T (lt) | Kombinacinės terapijos chemoresistencinių vėžių gydymui | |
| EP2758373A4 (en) | PROCESS FOR PREPARING N-ETHYL-2-METHYLPYRIDINBROMIDE AND N-ETHYL-3-METHYLPYRIDINE BROMIDE | |
| HUE046508T2 (hu) | Orvepitant krónikus viszketés kezelésére | |
| IL235455B (en) | A systematic method for determining the relative benefit of anticancer drugs | |
| PL2972368T3 (pl) | Biomarkery limfocytów do określania odpowiedzi klinicznej na terapię komórkową | |
| FR2988539B1 (fr) | Systeme d'emission-reception en bande millimetrique | |
| EP2758777A4 (en) | DETECTION OF OVARIAN CANCER | |
| EP3006942A4 (en) | REAGENT WITH ANTI-LGR6 ANTIBODIES FOR THE DETECTION AND DIAGNOSIS OF CANCER |